VLA-4 and VCAM-1 in Advanced Atherosclerosis
VLA-4 和 VCAM-1 在晚期动脉粥样硬化中的作用
基本信息
- 批准号:7140037
- 负责人:
- 金额:$ 24.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-12-01 至 2010-11-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
There is considerable evidence supporting a causal role for T-lymphocytes, monocytes, and monocytederived
macrophages in the initiation, progression, and complications of the atherosclerosis in man as
well as in experimental models. Plaque rupture is thought to be the trigger event for acute coronary
syndromes in man, and several mouse models of plaque rupture have recently been described. Lesion
macrophages in particular have been implicated in plaque rupture by releasing de-stabilizing proteases.
Notably, there is evidence for continued recruitment of circulating monocytes into arterial lesions in
experimental atherosclerosis, particularly in the rupture-prone shoulder. Moreover, adhesion receptors
may also regulate critical functions of emigrated leukocytes resident in lesions, including activation and
survival. Thus, the adhesion molecules that mediate monocyte trafficking into the arterial wall a potentially
attractive target in advanced as well as early disease.Studies to date of human and experimental lesions
suggest a significant role for endothelial VCAM-1 and its major leukocyte counter-receptor VLA-4 (cc4(31)
in the early phase of disease, but have not examined the role of VLA-4 or VCAM-1 in the progression of
established atherosclerosis or its late complications such as plaque rupture. Since antagonists of VLA-4
have already progressed to clinical trials in other indications, the importance of VLA-4 and VCAM-1
interactions in the progression and late complications of atherosclerosis is a clinically relevant question as
patients are most often identified in this stage of the disease.
We hypothesize that the VLA-4 and VCAM-1 play important roles in monocyte and T-lymphocyte
recruitment to advanced as well as early lesions and that disruption of these adhesion pathways will
reduce progression of established lesions and prevent plaque rupture. In order to test this hypothesis, we
will utilize a recently developed mouse model in which interferon-induced Cre-loxP-mediated deletion of
the ot4 gene can be achieved at any time post-natal. These a4-deleted animals will be studied in both the
ApoE-/- (Aim 1) and LDRL-/- (Aim 2) background, allowing us to define for the first time the contribution of
VLA-4 in the progression of established lesions and plaque rupture as well as in lesion initiation. To
complement the VLA-4 studies, we will also examine the role of VCAM-1 in lesion initiation/progression in
a model of conditional knockout of endothelial VCAM-1 (Aim 3).
有相当多的证据支持T淋巴细胞、单核细胞和单核细胞来源的因果关系
巨噬细胞在动脉粥样硬化的发生、发展和并发症中的作用
在实验模型中也是如此。斑块破裂被认为是急性冠状动脉病变的触发事件
最近描述了人类的症状和几种斑块破裂的小鼠模型。损伤
巨噬细胞通过释放不稳定的蛋白水解酶参与斑块破裂。
值得注意的是,有证据表明循环中的单核细胞持续募集到动脉病变中。
实验性动脉粥样硬化,特别是在易破裂的肩部。此外,黏附受体
也可以调节驻留在病变中的移居的白细胞的关键功能,包括激活和
生死存亡。因此,介导单核细胞进入动脉壁的黏附分子有可能
晚期和早期疾病中有吸引力的靶点:迄今对人类和实验性病变的研究
提示内皮细胞VCAM-1及其主要的白细胞对抗受体VLA-4(CC4(31))具有重要作用
在疾病的早期阶段,但没有研究VLA-4或VCAM-1在疾病进展中的作用
已确诊的动脉粥样硬化或其晚期并发症,如斑块破裂。由于VLA-4的拮抗剂
已经在其他适应症上进行了临床试验,VLA-4和VCAM-1的重要性
动脉粥样硬化进展和晚期并发症的相互作用是一个临床相关的问题,如
患者通常是在疾病的这个阶段被发现的。
我们推测VLA-4和VCAM-1在单核细胞和T淋巴细胞中起重要作用
对晚期和早期损伤以及这些粘连通路的破坏将
减少已建立的病变的进展,防止斑块破裂。为了检验这一假设,我们
将利用最近开发的一种小鼠模型,在该模型中,干扰素诱导的Cre-loxP介导的
Ot4基因可以在出生后的任何时间获得。这些A4缺失的动物将在两个
APOE-/-(目标1)和LDRL-/-(目标2)背景,使我们能够第一次定义
VLA-4在已建立的病变和斑块破裂的进展中以及在病变起始中的作用。至
作为对VLA-4研究的补充,我们还将研究VCAM-1在血管内皮细胞损伤发生/发展中的作用。
内皮细胞VCAM-1条件性基因敲除模型(目标3)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN Marshall HARLAN其他文献
JOHN Marshall HARLAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN Marshall HARLAN', 18)}}的其他基金
Endothelial Toll-Like Receptor-4 Signaling in Sepsis
脓毒症中的内皮 Toll 样受体 4 信号转导
- 批准号:
7031621 - 财政年份:2005
- 资助金额:
$ 24.84万 - 项目类别:
Endothelial Toll-Like Receptor-4 Signaling in Sepsis
脓毒症中的内皮 Toll 样受体 4 信号转导
- 批准号:
7418682 - 财政年份:2005
- 资助金额:
$ 24.84万 - 项目类别:
Endothelial Toll-Like Receptor-4 Signaling in Sepsis
脓毒症中的内皮 Toll 样受体 4 信号转导
- 批准号:
6923080 - 财政年份:2005
- 资助金额:
$ 24.84万 - 项目类别:
VLA-4 And VCAM-1 in Advanced Atherosclerosis
VLA-4 和 VCAM-1 在晚期动脉粥样硬化中的作用
- 批准号:
6858453 - 财政年份:2005
- 资助金额:
$ 24.84万 - 项目类别:
Endothelial Toll-Like Receptor-4 Signaling in Sepsis
脓毒症中的内皮 Toll 样受体 4 信号转导
- 批准号:
7226200 - 财政年份:2005
- 资助金额:
$ 24.84万 - 项目类别:
相似国自然基金
卡路里限制的T细胞糖脂代谢重塑机制及网络调控
- 批准号:91957111
- 批准年份:2019
- 资助金额:80.0 万元
- 项目类别:重大研究计划
高尿酸血症促进动脉粥样硬化机制探讨
- 批准号:81170251
- 批准年份:2011
- 资助金额:14.0 万元
- 项目类别:面上项目
大麻素CB2受体:巨噬细胞efferocytosis功能调控和不稳定斑块防治的新靶点
- 批准号:81000086
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
磷脂转运蛋白通过磷酸鞘氨醇1影响高密度脂蛋白抗动脉粥样硬化功能的分子机制
- 批准号:81070247
- 批准年份:2010
- 资助金额:33.0 万元
- 项目类别:面上项目
抑制PI3K/Akt/mTOR/p70S6K 信号通路促进巨噬细胞自体吞噬稳定易损斑块的分子机制研究
- 批准号:30971216
- 批准年份:2009
- 资助金额:31.0 万元
- 项目类别:面上项目
基因缺失突变抑制白细胞趋化稳定动脉粥样硬化易损斑块的研究
- 批准号:30871040
- 批准年份:2008
- 资助金额:32.0 万元
- 项目类别:面上项目
相似海外基金
Identifying the Role of Sex Hormones in Carotid Atherosclerotic Plaque Instability
确定性激素在颈动脉粥样硬化斑块不稳定中的作用
- 批准号:
494557 - 财政年份:2023
- 资助金额:
$ 24.84万 - 项目类别:
Operating Grants
Smooth muscle cell-derived cell fates and cellular interactions in atherosclerotic plaque stability in disease progression and regression.
平滑肌细胞衍生的细胞命运和细胞相互作用在疾病进展和消退中动脉粥样硬化斑块的稳定性。
- 批准号:
10567844 - 财政年份:2023
- 资助金额:
$ 24.84万 - 项目类别:
Identification of smooth muscle cell genes causal in atherosclerotic plaque stability and cardiovascular disease risk
鉴定导致动脉粥样硬化斑块稳定性和心血管疾病风险的平滑肌细胞基因
- 批准号:
10720225 - 财政年份:2023
- 资助金额:
$ 24.84万 - 项目类别:
Endothelial Cell Respiration in Atherosclerotic Plaque Erosion
动脉粥样硬化斑块糜烂中的内皮细胞呼吸
- 批准号:
10586227 - 财政年份:2023
- 资助金额:
$ 24.84万 - 项目类别:
Mechanistic registry to study whether infection with Corona Virus Disease 2019 (COVID-19) accelerates atherosclerotic plaque progression
研究 2019 年冠状病毒病 (COVID-19) 感染是否加速动脉粥样硬化斑块进展的机制登记
- 批准号:
10482402 - 财政年份:2022
- 资助金额:
$ 24.84万 - 项目类别:
Carotid Atherosclerotic Plaque Instability: what's sex got to do with it?
颈动脉粥样硬化斑块不稳定:性别与它有什么关系?
- 批准号:
455156 - 财政年份:2021
- 资助金额:
$ 24.84万 - 项目类别:
Fellowship Programs
Role of Smooth Muscle-derived Vascular Progenitor Cells (AdvSca1-SM) in Vasa Vasorum Expansion and Atherosclerotic Plaque Progression
平滑肌源性血管祖细胞 (AdvSca1-SM) 在血管滋养管扩张和动脉粥样硬化斑块进展中的作用
- 批准号:
10686163 - 财政年份:2021
- 资助金额:
$ 24.84万 - 项目类别:
Mechanistic registry to study whether infection with Corona Virus Disease 2019 (COVID-19) alters atherosclerotic plaque progression
研究 2019 年冠状病毒病 (COVID-19) 感染是否会改变动脉粥样硬化斑块进展的机制登记
- 批准号:
10280423 - 财政年份:2021
- 资助金额:
$ 24.84万 - 项目类别:
Role of Smooth Muscle-derived Vascular Progenitor Cells (AdvSca1-SM) in Vasa Vasorum Expansion and Atherosclerotic Plaque Progression
平滑肌源性血管祖细胞 (AdvSca1-SM) 在血管滋养管扩张和动脉粥样硬化斑块进展中的作用
- 批准号:
10582515 - 财政年份:2021
- 资助金额:
$ 24.84万 - 项目类别:
Determining the role of endothelial activation on microRNA communication in atherosclerotic plaque: towards identifying of a novel therapeutic target in carotid disease
确定内皮激活对动脉粥样硬化斑块中 microRNA 通讯的作用:确定颈动脉疾病的新治疗靶点
- 批准号:
416180 - 财政年份:2019
- 资助金额:
$ 24.84万 - 项目类别:
Studentship Programs